Jim Simons
CTIC

Jim Simons’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Jim Simons’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,520
Closed -$154K – 4588
2022
Q3 		$154K Sell
26,520
-417,093
-94% -$2.6M ﹤0.01% 3469
2022
Q2 		$2.65M Sell
443,613
-667,800
-60% -$3.42M ﹤0.01% 1989
2022
Q1 		$5.19M Sell
1,111,413
-244,000
-18% -$728K 0.01% 1565
2021
Q4 		$3.36M Sell
1,355,413
-434,085
-24% -$1.06M ﹤0.01% 1784
2021
Q3 		$5.28M Sell
1,789,498
-648,935
-27% -$1.77M 0.01% 1434
2021
Q2 		$6.1M Buy
2,438,433
+827,620
+51% +$1.98M 0.01% 1502
2021
Q1 		$4.69M Sell
1,610,813
-188,358
-10% -$615K 0.01% 1689
2020
Q4 		$5.79M Sell
1,799,171
-396,436
-18% -$1.32M 0.01% 1494
2020
Q3 		$4.72M Buy
2,195,607
+91,815
+4% +$117K ﹤0.01% 1614
2020
Q2 		$2.44M Buy
2,103,792
+17,668
+0.8% +$18.7K ﹤0.01% 2082
2020
Q1 		$1.92M Buy
2,086,124
+118,210
+6% +$135K ﹤0.01% 2074
2019
Q4 		$3.11M Buy
1,967,914
+90,025
+5% +$85.3K ﹤0.01% 2106
2019
Q3 		$1.57M Buy
1,877,889
+281,302
+18% +$215K ﹤0.01% 2407
2019
Q2 		$1.37M Buy
1,596,587
+314,235
+25% +$290K ﹤0.01% 2546
2019
Q1 		$1.24M Buy
1,282,352
+195,103
+18% +$205K ﹤0.01% 2573
2018
Q4 		$798K Buy
1,087,249
+325,688
+43% +$535K ﹤0.01% 2682
2018
Q3 		$1.65M Sell
761,561
-11,884
-2% -$29.4K ﹤0.01% 2377
2018
Q2 		$3.85M Buy
773,445
+84,500
+12% +$370K ﹤0.01% 1945
2018
Q1 		$2.69M Buy
688,945
+79,096
+13% +$278K ﹤0.01% 2163
2017
Q4 		$1.63M Buy
609,849
+198,700
+48% +$582K ﹤0.01% 2456
2017
Q3 		$1.31M Buy
411,149
+274,404
+201% +$916K ﹤0.01% 2469
2017
Q2 		$453K Buy
136,745
+17,400
+15% +$67.7K ﹤0.01% 2790
2017
Q1 		$501K Sell
119,345
-54,704
-31% -$252K ﹤0.01% 2771
2016
Q4 		$709K Sell
174,049
-22,636
-12% -$93.9K ﹤0.01% 2664
2016
Q3 		$736K Buy
196,685
+165,131
+523% +$601K ﹤0.01% 2690
2016
Q2 		$107K Buy
31,554
+30,334
+2,486% +$139K ﹤0.01% 3153
2016
Q1 		$6K Buy
+1,220
New +$9.75K ﹤0.01% 3348
2015
Q3 		– Sell
-56,112
Closed -$1.09M – 3619
2015
Q2 		$1.09M Buy
+56,112
New +$1.08M ﹤0.01% 2403
2015
Q1 		– Sell
-58,792
Closed -$1.39M – 3550
2014
Q4 		$1.39M Sell
58,792
-42,295
-42% -$978K ﹤0.01% 1974
2014
Q3 		$2.45M Buy
101,087
+31,822
+46% +$827K 0.01% 1568
2014
Q2 		$1.95M Buy
+69,265
New +$2.08M ﹤0.01% 1746
2014
Q1 		– Sell
-28,575
Closed -$546K – 3263
2013
Q4 		$546K Buy
+28,575
New +$520K ﹤0.01% 2330

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Jim Simons's CTIC Position: Q4 2022 in Review

Jim Simons sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 26,520 shares — an estimated $154K sold.

Jim Simons first reported a position in CTIC in Q4 2013 and held it in 32 quarters. The position peaked at $6.1M in Q2 2021. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • Jim Simons reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • Jim Simons sold 26,520 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $154K.
  • Jim Simons first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2013 and held it in 32 quarters.
  • Jim Simons's CTI BioPharma Corp. (DE) Common Stock position peaked at $6.1M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.